Výsledky vyhledávání - "Masae Sekido"

Akademický článek

Evaluation of the initial timing of infection control pharmacist-driven audit and monitoring of vancomycin therapy in patients with infectious diseases: A retrospective observational study

Autor: Hideki Sugita, Natsumi Okada, Matoka Okamoto, Masakazu Abe, Masae Sekido, Michiko Tanaka, Tatsuro Tamatukuri, Yuika Naito, Masayuki Yoshikawa, Eisuke Inoue, Hironori Tanaka

Publikováno v: PLoS ONE, Vol 18, Iss 8 (2023)

Background Early monitoring and feedback on the treatment of infectious diseases are some of the methods for optimising antimicrobial treatment throughout the treatment period. Prospective audits and feedback interventions have also been shown to imp

Externí odkaz: https://doaj.org/article/5fae73608a134e9d8a9edc8a28518a65

Zobrazit plný text záznamu

Plný text ve formátu HTML

Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, and 5-fluorouracil

Autor: Motoko Shibanuma, Fumihiro Ishikawa, Ken-ichi Fujita, Yasutsuna Sasaki, Takuya Tsunoda, Ryotaro Ohkuma, Hiroo Ishida, Takehiro Takahashi, Masae Sekido, Yutaro Kubota

Publikováno v: Cancer Chemotherapy and Pharmacology. 83:1127-1135

Several retrospective studies have shown that the antitumor efficacy of capecitabine-containing chemotherapy decreases when co-administered with a proton pump inhibitor (PPI). Although a reduction in capecitabine absorption by PPIs was proposed as th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bccad5389813839a7e5745343968bd6
https://doi.org/10.1007/s00280-019-03837-y

Zobrazit plný text záznamu

Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients

Autor: Ken-ichi Fujita, Natsumi Matsumoto, Hiroo Ishida, Masae Sekido, Ryotaro Ohkuma, Atsushi Hisamatsu, Yutaro Kubota, Kouji Kobayashi, Tomoyuki Ishiguro, Ken Shimada, Takuya Tsunoda, Toshikazu Ikusue, Hirokazu Toshima, Hirotsugu Ariizumi, Yuya Hirasawa

Publikováno v: Cancer chemotherapy and pharmacology. 85(6)

Capecitabine is a prodrug that undergoes metabolism in three steps to form an active 5-fluorouracil (5-FU). The first step is primarily catalyzed by liver carboxylesterases (CES) 1. Here, we examined the effects of CES1 variants on pharmacokinetics a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7070145bddedaab50733a3c8b1f61777
https://pubmed.ncbi.nlm.nih.gov/32458030

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání